FunPep Company Limited (TSE: 4881)
Health Care · Biotechnology · JP
¥51.00
+2.00% today · -56.4% 1Y
FunPep Company Limited (TSE: 4881) operates in the Biotechnology industry within the Health Care sector. The company is valued at $16.25M and employs 15 people.
Over the last twelve months the share price has lost 56.4%, trading between 45.00 and 130.00.
Tweenvest scores FunPep Company Limited across four factors: quality 29/100. Its strongest factor is quality.
4881 price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $16.25M
- Revenue (TTM)
- $6.15K
- P/E
- —
- EPS
- -37.08
- Dividend yield
- —
- Beta (5Y)
- 0.81
- 52-week high
- ¥130.00
- 52-week low
- ¥45.00
- Avg volume (3M)
- —
- Shares outstanding
- 50.67M
- Employees
- 15
- Next earnings
- —
About FunPep Company Limited
FunPep Company Limited specializes in the discovery and advancement of pharmaceutical drugs, functional cosmetics, and medical devices, leveraging its core technology in functional peptides. The company's development pipeline prominently features SR-0379, a functional peptide designed to address skin ulcers. FunPep is advancing FPP003, an antibody-inducing peptide, which is undergoing Phase II clinical trials for psoriasis in Australia and for ankylosing spondylitis in Japan. Another antibody-inducing peptide, FPP004X, is also in development, targeting pollinosis. Additionally, the company is working on FPP006, a corona peptide vaccine, and FPP005, an antibody-inducing peptide for psoriasis. Established in 2013, FunPep Company Limited operates from its headquarters in Tokyo, Japan.
- ISIN
- JP3802640007
- Founded
- 2013
- Listed since
- Dec 25, 2020
- Exchange
- The Tokyo Stock Exchange
- Currency
- JPY
Other Biotechnology companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| AbbVie Inc.NYSE: ABBV | $467.44B | $264.52 | -0.17% |
| Amgen Inc.NasdaqGS: AMGN | $239.95B | $443.84 | +1.03% |
| Gilead Sciences, Inc.NasdaqGS: GILD | $181.95B | $146.74 | +0.42% |
| Vertex Pharmaceuticals IncorporatedNasdaqGS: VRTX | $138.79B | $547.59 | -0.08% |
| Regeneron Pharmaceuticals, Inc.NasdaqGS: REGN | $82.73B | $828.50 | -0.66% |
| argenx SEENXTBR: ARGX | $63.06B | €874.20 | +1.16% |
| CSL LimitedASX: CSL | $57.94B | AU$169.11 | +0.48% |
| Moderna, Inc.NasdaqGS: MRNA | $55.45B | $141.77 | +2.07% |
Figures last refreshed Aug 18, 2026.